

ForPatients

by Roche

Breast Cancer

Effect of GDC-0810 on the Pharmacokinetics of Pravastatin in Healthy Female Subjects of Non-Childbearing Potential

Trial Status
Completed

Trial Runs In
1 Countries

Trial Identifier
NCT02621957 GP29825

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

Trial Summary:

This study is to assess the pharmacokinetics (PK) of a single dose of pravastatin with and without concomitant GDC-0810 administration in healthy female subjects of non-childbearing potential. During Period 1 (Day -1 to Day 4) PK parameters of pravastatin will be determined in the absence of GDC-0810. During Period 2 (Days 5-28) PK parameters of pravastatin will be determined in the presence of GDC-0810.

Genentech, Inc.
Sponsor

Phase 1
Phase

NCT02621957 GP29825
Trial Identifiers

Eligibility Criteria:

Gender
Female

Age
>= 18 Years & <= 65 Years

Healthy Volunteers
Accepts Healthy Volunteers

Risk factors for Lung Cancer

Researchers do not know the exact cause of Lung Cancer. However, certain risk factors have been linked to NSCLC. Here are just some of the known risk factors for Lung Cancer:

- Smoking.

This remains the main link to Lung Cancer. However, nonsmokers can also get Lung Cancer.

- Exposure to secondhand smoke.

ForPatients

by Roche

If you live in a house with smokers, you can be at risk for Lung Cancer.

- Environmental factors.
Exposure to radon and asbestos increases your risk. Air pollution, such as diesel fuel exhaust, may also be a risk factor for Lung Cancer.
- Family history.

You may be at greater risk for NSCLC or SCLC if a family member has had this type of lung cancer.

The advanced stages of lung cancer

Staging describes how far the disease has spread within the lungs or to other parts of the body. Staging affects the type of treatment you receive, your outcome (prognosis), and your eligibility for the atezolizumab clinical trials. These trials are for patients with advanced NSCLC — stage III or stage IV.